• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer

by MM360 Staff | Apr 30, 2025 | Uncategorized

Source: CureToday articles Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer. Read More

CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer

by MM360 Staff | Apr 30, 2025 | Uncategorized

Source: CureToday articles CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study. Read More

Lingering Stress After Follicular Lymphoma Remission is a Challenge

by MM360 Staff | Apr 30, 2025 | Uncategorized

Source: CureToday articles Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me. Read More

Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

by MM360 Staff | Apr 30, 2025 | Uncategorized

Source: CureToday articles Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer. Read More

SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia

by MM360 Staff | Apr 30, 2025 | Uncategorized

Source: CureToday articles A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia. Read More

An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC

by MM360 Staff | Apr 29, 2025 | Uncategorized

Source: CureToday articles The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT